Meiji Seika Pharma announced Tuesday that it plans to apply in Japan to sell its self-amplifying mRNA vaccine for Covid-19 and supply it for the fall/winter season.
TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that positive findings from the phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, in patients with plaque psoriasis conducted in the United States and Canada (NCT05268016) were presented on 12 October at the European Association of Dermatology and Venereology (EADV) Congress 2023 held in Berlin.
Meiji Seika Pharma Co., Ltd. reported that Adcock Ingram Pharma, an affiliated company of Medreich Ltd., completed construction of a new manufacturing facility in Bengaluru, India, to expand production capacity for its contract manufacturing organization (CMO) business.
ST. PAUL, Minn., May 31, 2023 /PRNewswire/ -- Applying its leadership in biopharma filtration technology, 3M (NYSE: MMM) today announced it will invest $146 million dollars to expand its capabilities to further support biotech manufacturing, a fast-growing area of health care which is bringing breakthrough therapies to patients.
A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe
Meijisubsidiary Meiji Seika Pharma has commenced a Phase III clinical trial of a messenger ribonucleic acid (mRNA) vaccine, ARCT-154, for Covid-19 in Japan.
TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) today announced that the first patient was dosed in Phase II clinical trial of ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, in patients with plaque psoriasis in the United States and Canada.
TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd.* (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) today announced that it has successfully completed Phase I clinical trials of ME3183, a selective PDE4 inhibitor, conducted in the United States. ME3183 has been shown to be safe and well-tolerated across the doses tested.
TOKYO--(BUSINESS WIRE)-- Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, “Meiji”) today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, “Dong-A”).